Celecoxib inhibits Helicobacter pylori colonization-related factors.
OBJECTIVE
To investigate the effect of celecoxib, a selective COX-2 inhibitor, on Helicobacter pylori (H. pylori) colonization-related factors and its mechanism.


METHODS
After co-incubation with celecoxib, morphology of H. pylori strain 26695 was observed under a transmission electron microscope. Flagella motility was assessed by stab agar motility test. Adherence of H. pylori to AGS cells was determined by enzyme linked immunosorbent assay. Levels of mRNA expression in flagellar genes (flaA, flaB), urease genes (ureA, ureB) and adhesin genes (babA, sabA, alpA, alpB, hpaA, hopZ) were measured by real-time polymerase chain reaction.


RESULTS
Separation and non-integrity of bacterial cell wall, rarefaction and asymmetry of cytoplasm, and even lysis of H. pylori were observed in the presence of celecoxib. When H. pylori strains were incubated in the presence of celecoxib, their flagellar motility and adherence to AGS cells were inhibited. The expression of ureA, ureB, babA, sabA, alpA, alpB, hpaA, hopZ was up-regulated while the expression of flaA, flaB was down-regulated in the presence of celecoxib.


CONCLUSIONS
Celecoxib inhibits flagellar motility and adherence of H. pylori to AGS cells, and destructs their normal structure in vitro.
Department of Gastroenterology, Peking University First Hospital, 8 Xishiku Avenue, Xicheng District, Beijing 100034, China.
Jing
J
Wang
Wei-Hong
WH
Wang
Jiang
J
Li
Fang-Xun
FX
Liu
D018829:Adhesins, Bacterial / Q000235:genetics; D001422:Bacterial Adhesion / Q000187:drug effects; D000068579:Celecoxib; D045744:Cell Line, Tumor; D052246:Cyclooxygenase 2 Inhibitors / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004797:Enzyme-Linked Immunosorbent Assay; D005407:Flagella / Q000187:drug effects / Q000648:ultrastructure; D005408:Flagellin / Q000235:genetics; D005753:Gastric Mucosa / Q000187:drug effects* / Q000382:microbiology / Q000473:pathology; D015964:Gene Expression Regulation, Bacterial / Q000187:drug effects; D016480:Helicobacter pylori / Q000187:drug effects* / Q000235:genetics / Q000254:growth & development / Q000472:pathogenicity / Q000648:ultrastructure; D006801:Humans; D046529:Microscopy, Electron, Transmission; D009068:Movement; D011720:Pyrazoles / Q000494:pharmacology*; D012329:RNA, Bacterial / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013449:Sulfonamides / Q000494:pharmacology*; D014510:Urease / Q000235:genetics
D018829:Adhesins, Bacterial; D052246:Cyclooxygenase 2 Inhibitors; D011720:Pyrazoles; D012329:RNA, Bacterial; D012333:RNA, Messenger; D013449:Sulfonamides; D005408:Flagellin; D014510:Urease; D000068579:Celecoxib